Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 4/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30467669 | 0.91 | F2 (0.40) | DHFRCSF1RLPLLIPGSNCA | |
| SCHEMBL24252626 | 0.84 | DHFR (0.39) | DHFRCSF1RLPLLIPGSNCA | |
| SCHEMBL24252617 | 0.81 | DHFR (0.31) | DHFR | |
| SCHEMBL24252272 | 0.81 | CSF1R (0.40) | DHFRCSF1RLPLLIPGSNCA | |
| SCHEMBL30467648 | 0.77 | CYP1A2 (0.43) | MEN1KMT2A | |
| SCHEMBL24252399 | 0.77 | CYP1A2 (0.43) | MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL30467784 | 0.77 | C1S (0.42) | DHFRCSF1RLIPGPDGFRBKDR | |
| SCHEMBL30467616 | 0.76 | DHFR (0.41) | DHFRCSF1RLPLLIPGSNCA | |
| SCHEMBL24252713 | 0.76 | DHFR (0.41) | DHFRCSF1RLPLLIPGSNCA | |
| SCHEMBL24252675 | 0.74 | DHFR (0.46) | DHFRRAD52MEN1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | DHFR 1380/4885CSF1R 963/4885LPL 321/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | DHFR 1380/4885CSF1R 963/4885LPL 321/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | DHFR 1380/4885CSF1R 963/4885LPL 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.